These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

553 related items for PubMed ID: 21946459

  • 1. Effects of anti-tumor necrosis factor agents for familial mediterranean fever patients with chronic arthritis and/or sacroiliitis who were resistant to colchicine treatment.
    Bilgen SA, Kilic L, Akdogan A, Kiraz S, Kalyoncu U, Karadag O, Ertenli I, Dogan I, Calguneri M.
    J Clin Rheumatol; 2011 Oct; 17(7):358-62. PubMed ID: 21946459
    [Abstract] [Full Text] [Related]

  • 2. Successful treatment with anti-tumor necrosis factor (anti-TNF)-alpha of proteinuria in a patient with familial mediterranean fever (FMF) resistant to colchicine: anti-TNF drugs and FMF.
    Erten S, Erten SF, Altunoglu A.
    Rheumatol Int; 2012 Apr; 32(4):1095-7. PubMed ID: 21431291
    [Abstract] [Full Text] [Related]

  • 3. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.
    Finckh A, Ciurea A, Brulhart L, Kyburz D, Möller B, Dehler S, Revaz S, Dudler J, Gabay C, Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis.
    Arthritis Rheum; 2007 May; 56(5):1417-23. PubMed ID: 17469098
    [Abstract] [Full Text] [Related]

  • 4. Effectiveness of a third tumor necrosis factor-α-blocking agent compared with rituximab after failure of 2 TNF-blocking agents in rheumatoid arthritis.
    Blom M, Kievit W, Donders AR, den Broeder AA, Straten VH, Kuper I, Visser H, Jansen TL, Brus HL, Branten AJ, van de Laar MA, van Riel PL.
    J Rheumatol; 2011 Nov; 38(11):2355-61. PubMed ID: 21885487
    [Abstract] [Full Text] [Related]

  • 5. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
    Barra L, Pope JE, Payne M.
    J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267
    [Abstract] [Full Text] [Related]

  • 6. Persistent periodontal disease hampers anti-tumor necrosis factor treatment response in rheumatoid arthritis.
    Savioli C, Ribeiro AC, Fabri GM, Calich AL, Carvalho J, Silva CA, Viana VS, Bonfá E, Siqueira JT.
    J Clin Rheumatol; 2012 Jun; 18(4):180-4. PubMed ID: 22647860
    [Abstract] [Full Text] [Related]

  • 7. The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever.
    Calligaris L, Marchetti F, Tommasini A, Ventura A.
    Eur J Pediatr; 2008 Jun; 167(6):695-6. PubMed ID: 17588171
    [Abstract] [Full Text] [Related]

  • 8. The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug.
    Söderlin MK, Petersson IF, Geborek P.
    Scand J Rheumatol; 2012 Feb; 41(1):1-9. PubMed ID: 22118371
    [Abstract] [Full Text] [Related]

  • 9. Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever.
    Şahin A, Derin ME, Albayrak F, Karakaş B, Karagöz Y.
    Adv Rheumatol; 2020 Jan 30; 60(1):12. PubMed ID: 32000860
    [Abstract] [Full Text] [Related]

  • 10. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
    Braun-Moscovici Y, Markovits D, Rozin A, Toledano K, Nahir AM, Balbir-Gurman A.
    Isr Med Assoc J; 2008 Apr 30; 10(4):277-81. PubMed ID: 18548981
    [Abstract] [Full Text] [Related]

  • 11. Familial Mediterranean fever successfully treated with etanercept.
    Mor A, Pillinger MH, Kishimoto M, Abeles AM, Livneh A.
    J Clin Rheumatol; 2007 Feb 30; 13(1):38-40. PubMed ID: 17278949
    [Abstract] [Full Text] [Related]

  • 12. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease.
    Cepeda EJ, Williams FM, Ishimori ML, Weisman MH, Reveille JD.
    Ann Rheum Dis; 2008 May 30; 67(5):710-2. PubMed ID: 18079191
    [Abstract] [Full Text] [Related]

  • 13. [Correlation between different clinical activity and anti CC-P (anti-cyclic citrullinated peptide antibodies) titres in rheumatoid arthritis treated with three different tumor necrosis factors TNF-alpha blockers].
    Benucci M, Turchini S, Parrochi P, Boccaccini P, Manetti R, Cammelli E, Manfredi M.
    Recenti Prog Med; 2006 Mar 30; 97(3):134-9. PubMed ID: 16700418
    [Abstract] [Full Text] [Related]

  • 14. Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-naive rheumatoid arthritis.
    Fernández-Nebro A, Irigoyen MV, Ureña I, Belmonte-López MA, Coret V, Jiménez-Núñez FG, Díaz-Cordovés G, López-Lasanta MA, Ponce A, Rodríguez-Pérez M, Calero E, González-Santos P.
    J Rheumatol; 2007 Dec 30; 34(12):2334-42. PubMed ID: 17985409
    [Abstract] [Full Text] [Related]

  • 15. Anti-Ro/SSA antibodies are an independent factor associated with an insufficient response to tumor necrosis factor inhibitors in patients with rheumatoid arthritis.
    Matsudaira R, Tamura N, Sekiya F, Ogasawara M, Yamanaka K, Takasaki Y.
    J Rheumatol; 2011 Nov 30; 38(11):2346-54. PubMed ID: 21965648
    [Abstract] [Full Text] [Related]

  • 16. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients.
    Seitz M, Wirthmüller U, Möller B, Villiger PM.
    Rheumatology (Oxford); 2007 Jan 30; 46(1):93-6. PubMed ID: 16720636
    [Abstract] [Full Text] [Related]

  • 17. [Serum levels of myeloid-related protein MRP 8/14 (calprotectin) in Armenian patients with familial mediterranean fever].
    Dzhndoian ZT.
    Ter Arkh; 2012 Jan 30; 84(6):45-8. PubMed ID: 22997918
    [Abstract] [Full Text] [Related]

  • 18. Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study.
    Mancarella L, Bobbio-Pallavicini F, Ceccarelli F, Falappone PC, Ferrante A, Malesci D, Massara A, Nacci F, Secchi ME, Manganelli S, Salaffi F, Bambara ML, Bombardieri S, Cutolo M, Ferri C, Galeazzi M, Gerli R, Giacomelli R, Grassi W, Lapadula G, Cerinic MM, Montecucco C, Trotta F, Triolo G, Valentini G, Valesini G, Ferraccioli GF, GISEA group.
    J Rheumatol; 2007 Aug 30; 34(8):1670-3. PubMed ID: 17611987
    [Abstract] [Full Text] [Related]

  • 19. Dosage adjustment of anti-tumor necrosis factor-α inhibitor in ankylosing spondylitis is effective in maintaining remission in clinical practice.
    Paccou J, Baclé-Boutry MA, Solau-Gervais E, Bele-Philippe P, Flipo RM.
    J Rheumatol; 2012 Jul 30; 39(7):1418-23. PubMed ID: 22707611
    [Abstract] [Full Text] [Related]

  • 20. Anti-TNF agents in familial Mediterranean fever: report of three cases and review of the literature.
    Ozgocmen S, Akgul O.
    Mod Rheumatol; 2011 Dec 30; 21(6):684-90. PubMed ID: 21567247
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.